je.st
news
Tag: asco
DelMar Pharmaceuticals Presents Additional Clinical Data from Ongoing Brain Cancer Study at ASCO
2013-06-04 09:45:49| Logistics - Topix.net
Activity with VAL-083 Observed in Recurrent Malignant Glioma and Progressive Secondary Brain Tumors Company Plans to Expand Clinical Development of VAL-083 /PRNewswire/ -- DelMar Pharmaceuticals, Inc.
Tags: data
additional
study
cancer
BerGenBio presents promising therapeutic candidate in AML at ASCO
2013-06-03 08:23:44| Logistics - Topix.net
BerGenBio AS, an emerging oncology biopharma company, has presented data on the importance of the receptor tyrosine kinase, Axl, in acute myeloid leukemia at the ASCO Annual Meeting 2013, in Chicago, IL.
Tags: presents
candidate
therapeutic
promising
EpiCept Announces New Crolibulin Data Presented at ASCO 2013 Support...
2013-06-03 07:18:32| Biotech - Topix.net
EpiCept Corporation today announced that new data supporting further evaluation of crolibulin were presented at the Annual Meeting of the American Society of Clinical Oncology , taking place May 31 to June 4, 2013 at the McCormick Place Convention Center in Chicago.
Tags: support
data
presented
announces
Merck Announces Presentation of Interim Data from Study Evaluating Lambrolizumab, an Investigational Anti-PD-1 Antibody, in Patients with Advanced Melanoma at ASCO 2013
2013-06-02 17:15:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. -Merck Expands Lambrolizumab Clinical Development Program- -Study Published Online in the New England Journal of Medicine- WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of preliminary results from an ongoing Phase IB expansion study evaluating the safety and efficacy of lambrolizumab (MK-3475), Mercks investigational antibody therapy targeting PD-1, in patients with advanced (inoperable and metastatic) melanoma. Language: English Contact HTML: MerckMedia Contacts:Ian McConnell, 973-901-5722Cathy Cantone, 908-327-3013orInvestor Contacts:Carol Ferguson, 908-500-1101Justin Holko, 609-915-8293 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
advanced
study
presentation
ASCO '13: Onyx's Nexavar Delays Growth of Thyroid Cancer
2013-06-02 14:50:11| Logistics - Topix.net
Nexavar stalled disease progression by five months in patients with treatment-resistant, differentiated thyroid cancer, an aggressive form of the disease that has gone without new, effective therapies for 40 years.
Tags: growth
cancer
delays
thyroid
Sites : [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] next »